^
Association details:
| Biomarker: | GPC3 expression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | CT017 (GPC-3-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial
Published date:
08/30/2023
Excerpt:
This single-center, single-arm, open-label, phase I clinical study enrolled heavily pretreated patients with GPC3-positive HCC between August 2019 and December 2020 (NCT03980288). Patients were treated with CT017 CAR T cells at a dose of 250 × 106 cells....Current preliminary phase I data showed a manageable safety profile and promising antitumor activities of CT017 for patients with advanced HCC.
DOI:
https://doi.org/10.1016/j.eclinm.2023.102175
Trial ID:
